⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511881 | 1.00 | — | — | |
| SCHEMBL2159081 | 1.00 | — | — | |
| SCHEMBL784551 | 0.87 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL13946795 | 0.87 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL12391130 | 0.82 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL5598798 | 0.80 | SMN1; SMN2 (0.48) | — | |
| SCHEMBL4011787 | 0.80 | SMN1; SMN2 (0.48) | — | |
| SCHEMBL7123594 | 0.79 | — | — | |
| SCHEMBL8871226 | 0.79 | — | — | |
| SCHEMBL8498697 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357207-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | BCP3 PTY LIMITED (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230348493-A1 | COMPOUND FOR ADJUSTING ACTIVITY OF NMDA RECEPTOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BEIJING GREATWAY PHARMACEUTICAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-9896688-B2 | Short interfering nucleic acid (siNA) molecules containing a 2′ internucleoside linkage | SIRNA THERAPEUTICS, INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20160279261-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH, INC. (US) | 2016-09-29 | — | — | US | disclosed |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160068837-A1 | SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES CONTAINING A 2' INTERNUCLEOSIDE LINKAGE | SIRNA THERAPEUTICS, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-9205124-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20100267669-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090005338-A1 | Carbonyl-substituted titanocenes | CHARITE - UNIVERSITATSMEDIZIN BERLIN (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005338-A1 | Carbonyl-substituted titanocenes | CHARITE - UNIVERSITATSMEDIZIN BERLIN (DE) | 2009-01-01 | — | — | US | disclosed |
| WO-2008059068-A2 | CARBONYL-SUBSTITUTED TITANOCENES | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2008-05-22 | — | — | WO | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |